Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

ESH AL 2020 | Germline predisposition to myeloid malignancies: emerging research

Lucy Godley • 1 Jul 2020

ESH AL 2020

Leukemia Myelodysplastic Syndromes

Lucy Godley, MD, PhD, University of Chicago, Chicago, IL, outlines upcoming research in germline predisposition syndromes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Germline predisposition to AML

Germline predisposition to AML

Lucy Godley • 1 Jul 2020

The impact of germline mutations on AML managment

The impact of germline mutations on AML managment

Lucy Godley • 1 Jul 2020

Related Videos

The value and mission of the International Workshop on Acute Leukemias

The value and mission of the International Workshop on Acute Leukemias

Charles Craddock et al. • 21 Oct 2025

One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?

One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?

Koichi Takahashi • 26 Sep 2025

One big question with Naval Daver: what AML advance could transform frontline care in three years?

One big question with Naval Daver: what AML advance could transform frontline care in three years?

Naval Daver • 26 Sep 2025

One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?

One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?

Charles Craddock • 26 Sep 2025